The effectiveness and safety of amisulpride in Chinese patients with schizophrenia: An 8‐week, prospective, open‐label, multicenter, single‐arm study. (28th March 2016)

• Record Type: Journal Article
• Authors: Liang, Ying; Cao, Changan; Zhu, Cheng; Wang, Chuanyue; Zhang, Congpei; Dong, Fang; Yang, Fude; Deng, Hong; Yu, Jingjie; Tang, Jisheng; Su, Lei; Xin, Limin; Hong, Ling; Gao, Minglong; Tang, Muni; Xie, Shiping; Lu, Shuiping; Liu, Tiebang; Xu, Xiaojin; Wang, Xijin; Li, Xuanzi; Wang, Xueyi; Li, Yi; Zhang, Yong; Chen, Zhiyu; Yu, Xin
• Is Part Of: Asia-Pacific psychiatry. Volume 8:Number 3(2016:Sep.)
• Page Start: 241
• Page End: 244
• Publication Date: 2016-03-28
• Subjects: amisulpride -- antipsychotic agents/adverse effects -- antipsychotic agents/therapeutic use -- Chinese -- Schizophrenia; Psychiatry -- Pacific Area -- Periodicals; 616.890095
• DOI: 10.1111/appy.12238
• Languages: English
• ISSNs: 1758-5864

Abstract

Abstract: Introduction: This study evaluated the effectiveness and safety of amisulpride in Chinese schizophrenia patients. Methods: A multicenter, single‐arm Phase IV study (NCT01795183). Chinese patients with schizophrenia received amisulpride for 8 weeks. The primary endpoint was ≥50% decrease in Positive and Negative Syndrome Scale total score from Baseline to Week 8. Results: A total of 316 patients were enrolled; 295 were included in the effectiveness analysis; 66.8% (197/295) achieved ≥50% decrease in Positive and Negative Syndrome Scale total score from Baseline to Week 8. Nine patients discontinued treatment because of adverse events. Discussion: Amisulpride had clinical effectiveness and was relatively well tolerated in Chinese patients with schizophrenia.